Eurofins Central Laboratory is pleased to announce that is has achieved an important strategic milestone with the expansion and relocation of its U.S. Central Laboratory Operations to the 330,000 square foot Eurofins Pharma Services campus in Lancaster, PA. The consolidation of the Central Laboratory into the Lancaster Laboratories campus, combined with the recently announced acquisitions of leading bioanalytical, discovery, genomic and diagnostic laboratories in the US, positions Eurofins as a leading full service laboratory provider to the pharmaceutical and biotech industries. This purpose built Central Laboratory is essential to the Eurofins Central Laboratory global footprint of wholly-owned laboratory facilities in the United States, Europe, Asia and China.
Dr. Charles J. DiComo, Vice President & General Manager, U.S. & Global Laboratory Operations, explains: “The Central Laboratory in Lancaster is fully harmonized and seamlessly aligned with our other Eurofins Central Laboratories. All laboratory equipment, analytical methods, standard operating procedures and quality standards are identical across laboratories to support clinical trials being conducted across regions by our clients. Operating in line with both GLP and GCP standards, and with a strong expertise in biomarker analysis, we are positioning ourselves to become the first-choice Central Laboratory for our pharmaceutical sponsors.”
Successfully operational since early April, the Eurofins Central Laboratory in Lancaster offers a full package of safety and esoteric testing. Furthermore, this location houses the Microbiology Center of Excellence for Eurofins Central Laboratory. The facility is accredited by the Pennsylvania Department of Health, CAP, CLIA and NGSP Level I.
Elena Logan, Global Vice President Sales & Marketing, remarks: “The expansion of our Central Laboratory services on the Lancaster campus signifies the importance of this business within the portfolio of offerings of Eurofins Pharma Services. The Central Laboratory is core to the integration of our other laboratory services and as such, we continue to make significant investments in the business to ensure customers receive first class service and optimal delivery of results to support key decision making during and as a result of the clinical trials being run with Eurofins.”